Yervoy (ipilimumab) alone doesn’t help treat advanced prostate cancer patients. Yervoy activates the immune system by going after the CTLA-4 protein receptor that slows immune-system activity. But prostate cancer responds to Yervoy by increasing two other immune checkpoint molecules, PD-L1 and VISTA. And both send a don’t-eat-me signal to immune cells. That reaction is why Yerboy, by [...]
New molecules called selective androgen receptor degraders (SARDs) might be helpful in fighting advanced prostate cancer, according to an industry-sponsored study presented April 1, at the 99th annual meeting of the Endocrine Society. "If successful in the clinic, the novel highly potent SARDs discovered in this program could be used to treat many of the [...]
Fetal estrogen estetrol, also called E4, is being tested in the Netherlands as a treatment for advanced prostate cancer. "E4 for the treatment of prostate cancer would offer a new and affordable option compared to current standard and new therapies. An important advantage of E4 is expected to be the avoidance of the hypoestrogenic side [...]
Researchers from the University and the Sichuan Antibiotics Industrial Institute in China have discovered a novel treatment for advanced prostate cancer. For over forty years, ADT has been the foundation of advanced stage prostate cancer treatment. ADT is effective initially, most often measured by a drop in PSA measurement. But in almost all cases, prostate [...]
There’s a better way to do a PET scan, by using radiotracer fluciclovine (fluorine-18; F-18) (Journal of Nuclear Medicine, March 2017) According to researcher Ashesh B. Jani, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia, fluciclovine can improve imaging in recurrent prostate cancer patients with no additional radiation side effects. An improved PET [...]
There's a new Phase 3 clinical trial for an oral medication, taken one time per day, that will reduce testosterone for advanced prostate cancer. Myovant Sciences is testing their new drug, called Relugolix in a trial called, HERO. Relugolix lowers testosterone by inhibiting pituitary release of luteinizing hormone and follicle-stimulating hormone. Todays testosterone reducing therapies require injections and [...]
Here is a newly emerged advocacy opportunity regarding the PSA test and Prostate Cancer in the USA. Malecare feels you should be empowered to participate in this national health policy issue. CMS' Center for Medicare issued what is known as a Medicare Advantage Call letter. In the letter, the CMS signals to Medicare Advantage Plans [...]
Men living in wealthier zip codes in the United States live longer with advanced prostate cancer than men in lower income zip codes. Creighton University, Omaha, NE researchers studied income levels and overall survival of men diagnosed with stage IV prostate cancer. Lead author Sabra Ahmed and his team looked at 50,639 men in the National Cancer Database diagnosed [...]
Rather than taking – and paying – for the full Zytiga dose on an empty stomach, ask your doctor if you could get the same effect from taking just one fourth of your Zytiga dose while enjoying a low-fat or high-fat breakfast. A small phase two study of 36 prostate cancer patients who took 250 [...]
All of us are affected by the recent refugee and travel ban. At one time or another, all of us have been helped by doctors, medical students, nurses, social workers, caregivers and fellow cancer patients who were born outside of the United States. Many of the treatments and drugs that keep us alive were developed [...]
